Comparison of Intravenous Immunoglobulin (IVIG) and Plasma Exchange in Children with Guillain-Barré Syndrome at a Tertiary Care Hospital in Lahore

Ambreen Aslam; Nighat Sultana; Samreen Ashraf; Momina Khan; Mahnaz Parveen; Muhammad Sarwar

doi:10.51253/pafmj.v76i3.12641

Authors

Ambreen Aslam Pediatric Intensive Care Unit, University of Child Health Sciences and The Children's Hospital Lahore, Pakistan
Nighat Sultana Pediatric Intensive Care Unit, University of Child Health Sciences and The Children's Hospital Lahore, Pakistan
Samreen Ashraf Pediatric Intensive Care Unit, University of Child Health Sciences and The Children's Hospital Lahore, Pakistan
Momina Khan Pediatric Intensive Care Unit, University of Child Health Sciences and The Children's Hospital Lahore, Pakistan
Mahnaz Parveen Pediatric Intensive Care Unit, University of Child Health Sciences and The Children's Hospital Lahore, Pakistan
Muhammad Sarwar Pediatric Intensive Care Unit, University of Child Health Sciences and The Children's Hospital Lahore, Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76i3.12641

Keywords:

Guillain-Barré Syndrome, IVIG, Pediatric ICU, Plasmapheresis

Abstract

Objective: To compare the outcome of IVIG and plasma exchange in treatment of Guillain-Barré Syndrome (GBS) in children.

Study Design: Retrospective Longitudinal Study

Place and Duration of Study: Pediatric Intensive Care Unit (PICU), University of Child Health Sciences and The Children's Hospital, Lahore, Pakistan, from Oct 22 to Sep 23.

Methodology: The study included all pediatric patients aged 1 to 14 years diagnosed with GBS admitted to the ICU. Retrospective data collection was done for the IVIG group, while prospective data collection was done for the plasmapheresis group. Demographics, hospitalization duration, mechanical ventilation period, treatment outcomes, and muscle power improvement were compared between the IVIG and plasmapheresis groups using the Medical Research Council (MRC) Score.

Results: Among 150 patients, 62.7% were male, with mean age 6.19 ± 3.81 years and mean weight 19.75 ± 10.62 kg. The most common EMG/NCS finding was AMAN. Average PICU stay was 33.32 ± 13.79 days, and ventilation duration was 29.22 ± 14.33 days. Both IVIG and plasma groups showed significant muscle power improvement (p < 0.05). IVIG patients had shorter PICU stays (27.39 ± 10.50 days) and ventilation durations (23.13 ± 11.56 days) than plasma patients (39.25 ± 14.20 days and 35.31 ± 14.31 days, respectively, p < 0.05).

Conclusion: Both IVIG and plasmapheresis are equally effective, but IVIG outperformed plasmapheresis regarding reduced duration of hospitalization and ventilation as well as need for tracheostomy.

Downloads

Download data is not yet available.

References

1. van Doorn PA, Van den Bergh PY, Hadden RD, Avau B, Vankrunkelsven P, Attarian S, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain–Barré syndrome. J Peripheral Nervous Sys 2023; 28(4): 535-563.

https://doi.org/10.1111/jns.12594

2. Ali T, Abou Fakher FH, Alawir M, Allababidi A, Hasan AS. Efficacy and Safety of Therapeutic Plasma Exchange in Pediatric Patients with Guillain-Barré Syndrome: A Retrospective Study.2024. https://doi.org/10.21203/rs.3.rs-3892021/v1

3. El-Anwar, N., Abdel Maksoud, F., Elsebaie, E., Hassan, M., Mohamed, S. Indications and Outcomes of Therapeutic Plasma Exchange in Critically ill Children at a University Children Hospital. J Egypt Soc Pediatr Nephrol Transplant 2023; 18(1): 35-42. https://doi.org/10.21608/geget.2023.308022

4. Khan MH, Islam MK, Rahman S, Rahman AF, Sarker SK, Mohsin M, et al. Effectiveness of Plasmapheresis and IVIG in the Treatment of Guillain-Barré Syndrome: A Cross-Sectional Observational Study. Bangladesh Critical Care J 2023; 11(2): 95-102. https://doi.org/10.3329/bccj.v11i2.69194

5. Saad K, Mohamad IL, Abd El-Hamed MA, Tawfeek MS, Ahmed AE, Abdel Baseer KA, et al. A comparison between plasmapheresis and intravenous immunoglobulin in children with Guillain–Barré syndrome in Upper Egypt. Ther Adv Neurol Disord 2016; 9(1): 3-8.

https://doi.org/10.1177/1756285615610471

6. Elahi E, Ashfaq M, Nisa BU, Chachar S. Plasma exchange versus intravenous immunoglobulin in children with Guillain Barré syndrome. J Dow Univ Health Sci 2019; 13(3): 133-137.

https://doi.org/10.36570/jduhs.2019.3.693

7. Bellanti R, Rinaldi S. Guillain-Barré syndrome: a comprehensive review. Eur J Neurol 2024; 31(8): e16365.

https://doi.org/10.1111/ene.16365

8. Langille MM. Guillain-Barre Syndrome in Children and Adolescents. Adv Pediatr. 2023; 70(1): 91-103.

https://doi.org/10.1016/j.yapd.2023.04.001

9. Mohy-Eldeen ZM, Ahmad AR, Mahran HH, Saad K. Comparative study of various therapeutic modalities for Guillain-Barré syndrome in Assiut University Children Hospital. Turk J Pediatr 2020; 62(6): 962-969.

https://doi.org/10.24953/turkjped.2020.06.007

10. Habib AA, Waheed W. Guillain-Barré Syndrome. Continuum 2023; 29(5): 1327-1356.

https://doi.org/10.1212/con.0000000000001289

11. Bragazzi NL, Kolahi AA, Nejadghaderi SA, Lochner P, Brigo F, Naldi A, et al. Global, regional, and national burden of Guillain–Barré syndrome and its underlying causes from 1990 to 2019. J Neuroinflammation 2021; 18(1): 264.

https://doi.org/10.1186/s12974-021-02319-4

12. Abbas M, Robert HM, Mehmood A, Ali N, Ayaz MA. Plasmapheresis in the treatment of Guillain‑Barré syndrome: outcomes and complications. J Postgrad Med Inst 2021; 34(3).

https://jpmi.org.pk/index.php/jpmi/article/view/2723

13. Altaf MS, Khurshid A, Maqsood I. Comparison of mean hospital stay in intravenous immunoglobulin vs. plasmapheresis in children with Guillain-Barré Syndrome in a Tertiary Care PICU. Prof Med J 2023; 30(07): 896-900.

https://doi.org/10.29309/tpmj/2023.30.07.7541

14. Ali T, Hkima Abou Fakher F, Alawir M, Allababidi A, Sheikh Hasan A. Management of severe pediatric Guillain-Barré syndrome in a low-income country: efficacy and safety of therapeutic plasma exchange in pediatric patients: a retrospective study. BMC Pediatr 2024; 24(1): 818.

https://doi.org/10.1186/s12887-024-05298-6

15. Nandeesha SS, Kasagga A, Hawrami C, Ricci E, Hailu KT, Salib K, et al. Treatment Efficacy of Plasmapheresis Versus Intravenous Immunoglobulin in Guillain-Barré Syndrome Management: A Systematic Review. Cureus 2024; 16(3): e57066.

https://doi.org/10.7759/cureus.57066

16. Mallick UK, Chowdhury MS, Hussain ME, Asaduzzaman M, Islam MS, Hoque MS, et al. Comparison of ICU outcomes between intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated patients with GuillainBarré syndrome in a neuro-intensive care unit in a Govt. Hospital of Bangladesh: a observational cohort study. J Nat Institute Neurosci Bangladesh 2019; 5(2): 118-22.

https://doi.org/10.3329/jninb.v5i2.43015

17. Beydoun HA, Beydoun MA, Hossain S, Zonderman AB, Eid SM. Nationwide study of therapeutic plasma exchange vs intravenous immunoglobulin in Guillain‐Barré syndrome. Muscle & Nerve 2020; 61(5): 608-615.

https://doi.org/10.1002/mus.26831

18. Anwer JA, Khalid SA, Haq RU, Iqbal RA, Mahmood ZA, Tayyab HA. Outcome of various treatments in Guillain–Barré syndrome in children. Pak J Med Health Sci 2020; 14(1): 296-298. https://pjmhsonline.com/2020/jan_march/pdf/296.pdf

19. Zaki HA, Iftikhar H, Najam M, Masood M, Al-Marri ND, Elgassim MA, et al. Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barré syndrome (GBS) in patients with severe symptoms: A systematic review and meta-analysis. Eneurologicalsci 2023; 31: 100468. https://doi.org/10.1016/j.ensci.2023.100468.